TheraRadar
Clinical-Stage Companies / Shenzhen Salubris Pharmaceuticals

Shenzhen Salubris Pharmaceuticals

Pre-Approval PRO BETA
20
Total Trials
9
Phase 3
2
Phase 2
4
Recruiting
197
Score

Pipeline by Phase

Phase 3
9
Phase 2
2
Phase 1
7

Therapeutic Focus

Renal Anemia in Non-dialysis Chronic Kidney Disease Anemia Essential Hypertension Diabetes Mellitus, Type 2 Primary Hypertension

Clinical Trials (20)

NCT07295418 Phase 3 COMPLETED

A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia

Started: 10/23/2023

NCT07253584 Phase 3 COMPLETED

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia

Started: 12/19/2023

NCT07028320 Phase 3 COMPLETED

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

Started: 12/3/2021

NCT06720025 Phase 3 COMPLETED

Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis

Started: 9/19/2023

NCT06016036 Phase 3 COMPLETED

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

Started: 12/8/2020

NCT06500689 Phase 3 COMPLETED

To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

Started: 12/30/2021

NCT06465264 Phase 3 COMPLETED

To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

Started: 4/29/2021

NCT05801627 Phase 3 COMPLETED

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin

Started: 5/6/2020

NCT05782192 Phase 3 COMPLETED

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Started: 6/13/2019

NCT06737081 Phase 2 RECRUITING

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Started: 9/14/2024

NCT07278830 Phase 2 COMPLETED

A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

Started: 6/2/2023

NCT07051603 Phase 1 RECRUITING

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

Started: 6/9/2025

NCT07486453 Phase 1 NOT YET RECRUITING

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

Started: 3/9/2026

NCT07384104 Phase 1 ENROLLING BY INVITATION

Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects

Started: 10/19/2025

NCT07030504 Phase 1 ACTIVE NOT RECRUITING

To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects

Started: 1/10/2023

NCT06883656 Phase 1 COMPLETED

The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency

Started: 3/15/2022

NCT06830954 Phase 1 NOT YET RECRUITING

Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants

Started: 2/1/2025

NCT04747392 Phase 1 COMPLETED

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

Started: 8/19/2020

NCT07174830 Phase 4 RECRUITING

Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants

Started: 9/6/2025

NCT07079579 Phase 4 NOT YET RECRUITING

Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

Started: 8/1/2025

Drug Candidates

Sequence A T-R-T-R Sequence B R-T-R-T SAL0123 Romosozumab SAL003 140 mg Placebo SAL003 140mg+Atorvastatin SAL003 420mg+Atorvastatin Placebo 140mg+Atorvastatin Placebo 420mg+Atorvastatin
Activity Status: Active
Last Trial Started: 3/9/2026
Last Trial Ended: 6/30/2025
Trials (12 months): 5
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.